A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.


Eligibility Criteria:
Inclusion Criteria:

* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
* 18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);
* Electrocorticogram (ECOG) score ranges from 0 to 1 points;
* Expected survival is greater than 12 weeks；
* Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；
* Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；
* Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.

Exclusion Criteria:

* Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;
* There are multiple factors that affect diseases related to intravenous injection and venous blood collection;
* The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;
* Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;
* Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;
* An arterial/venous thrombotic event occurred within 6 months prior to the first administration;
* Active viral hepatitis with poor control;
* Active syphilis infected individuals in need of treatment;
* History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;
* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;
* Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy due to a history of hepatic encephalopathy;
* Previously experienced grade 3 or higher adverse reactions related to immunotherapy;
* Suffering from significant cardiovascular disease;
* Active or uncontrolled severe infections;
* Patients with renal failure requiring hemodialysis or peritoneal dialysis;
* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;
* Individuals with epilepsy who require treatment;
* Previously received treatment with similar anti-lag3 drugs.